MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 892 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Z16078526
CAS:Z16078526 promotes Ucp1, p38 MAPK, lipolysis, thermogenic genes, and mitochondrial activity in mouse brown adipocytes.Fórmula:C18H17N3O4SPureza:99.18%Cor e Forma:SolidPeso molecular:371.41L-JNKI-1
L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK, it has been shown to effectively inhibit JNK activity in in vivo studies.Fórmula:C164H286N66O40Pureza:98%Cor e Forma:SolidPeso molecular:3822.44Tagarafdeg
CAS:Tagarafdeg (CFT1946) is a PROTAC degradator targeting mutant BRAF, capable of degrading BRAF V600E, G469A, G466V mutations, anti proliferation.Fórmula:C45H49F2N11O9SPureza:>99.99% - ＞99.99%Cor e Forma:SolidPeso molecular:958Rineterkib hydrochloride
CAS:Rineterkib hydrochloride (B) is an oral RAF/ERK1/2 inhibitor for MAPK-driven cancers, including KRAS/BRAF-mutant NSCLC and CRC.Fórmula:C26H28BrClF3N5O2Cor e Forma:SolidPeso molecular:614.89Pan-RAS-IN-6
Pan-RAS-IN-6 (compound 24) serves as a DUSP6 inhibitor, effectively reducing MAPK activation in the NCI-H1373-Luc model (DUSP6). It concurrently exhibits notable tumor growth inhibition and regression in the NSCLC brain metastasis mouse model. The compound displays high selectivity and potent inhibitory effects, particularly on KRAS mutation-associated signaling pathways. It demonstrates varied inhibitory activities against distinct KRAS mutants and their interacting proteins. The IC 50 values for KRAS G12C, G12D, and G12V are 1.3 nM, 4.7 nM, and 0.3 nM, respectively.Fórmula:C46H60N8O5SCor e Forma:SolidPeso molecular:837.08PROTAC MEK1 Degrader-1
CAS:PROTAC MEK1 Degrader-1, a targeted protein degradation agent, combines a MEK1 inhibitor with a von Hippel-Lindau ligand to effectively inhibit ERK1/2Fórmula:C53H66FIN8O11S2Pureza:98%Cor e Forma:SolidPeso molecular:1201.17U0124
CAS:Inactive analog of U0126(MEK-1/2 inhibitor), used as a negative controlFórmula:C8H10N4S2Pureza:98%Cor e Forma:SolidPeso molecular:226.32Pan-RAS-IN-7
CAS:Pan-RAS-IN-7 (Compound D101) is a broad-spectrum RAS inhibitor used in the synthesis of antibody-drug conjugates (ADCs). It is also applicable in cancer research.Fórmula:C59H76N8O8Cor e Forma:SolidPeso molecular:1025.28PROTAC SOS1 degrader-1
CAS:PROTAC SOS1 degrader-1: potent, DC50 98.4 nM, inhibits KRAS mutant cancer cells, low-toxic antitumor.Fórmula:C57H76O4ClFN10SCor e Forma:SoildPeso molecular:1050.54443BAS 00489700
CAS:BAS 00489700 is a N-UTR interaction inhibitor. BAS 00489700 inhibits virus replication in cell culture.Fórmula:C19H16N2O4Pureza:99.78%Cor e Forma:SolidPeso molecular:336.34Ref: TM-T67854
1mg89,00€5mg178,00€10mg264,00€25mg393,00€50mg552,00€100mg752,00€200mg1.008,00€1mL*10mM (DMSO)178,00€KRASG12C IN-14
KRASG12C IN-14 (compound 15), a potent inhibitor specifically designed for the KRAS G12C mutation, exhibits impressive efficacy in impeding CYPA-dependent KRAS-BRAF interaction and ERK phosphorylation in NCI-H358 cells, both with an IC 50 of 0.002 μM.Fórmula:C51H65F4N9O9S2Cor e Forma:SolidPeso molecular:1088.24MEK1/2-IN-3
MEK1/2-IN-3 (Compound M15) is an inhibitor of MEK1, with an IC50 value of 10.29 nM. It effectively suppresses tumor cell proliferation and migration, induces apoptosis, and exhibits good liver microsomal stability. MEK1/2-IN-3 is applicable in the study of solid tumors.Fórmula:C28H23F3IN3O4Cor e Forma:SolidPeso molecular:649.4(S)-BAY-293
CAS:<p>(S)-BAY-293 is a potent pan-KRAS inhibitor for the study of primary non-small lung and pancreatic cancers.</p>Fórmula:C25H28N4O2SPureza:98%Cor e Forma:SolidPeso molecular:448.58PDE4-IN-26
PDE4-IN-26 (Compound A5) is an orally active, highly selective inhibitor of PDE4. It exhibits anti-inflammatory properties by inhibiting p38 MAPK phosphorylation. In mouse models of acute lung injury and chronic obstructive pulmonary disease, PDE4-IN-26 reduces lung inflammation, damage, and fibrosis, while promoting sputum secretion and alleviating cough. It is useful for researching lung injury-related diseases.Fórmula:C22H18F2N4O3SCor e Forma:SolidPeso molecular:456.47DB-10
DB-10 serves as a precursor to 3-nbutylphthalide (NBP). It is absorbed by cells in a temperature and energy-dependent manner through the pyrilamine cation transporter. DB-10 enhances cell survival and rapidly converts into an active form in vivo, increasing accumulation within the brain. This compound is applicable in ischemic stroke research.Cor e Forma:Odour SolidPROTAC K-Ras Degrader-1
CAS:PROTAC K-Ras Degrader-1 is a PROTAC degrader based on the Cereblon E3 ligase ligand, capable of degrading K-Ras.Fórmula:C53H62N10O10Pureza:98.05%Cor e Forma:SolidPeso molecular:999.12LC 2 Epimer
CAS:<p>Negative control for LC 2.</p>Fórmula:C59H71ClFN11O7SCor e Forma:SolidPeso molecular:1132.8LYMTAC-2
LYMTAC-2 is a lysosome-targeting chimera (LYMTAC) developed to degrade membrane-associated proteins through lysosomal membrane proteins (LMP) such as RNF152, LAPTM4a, and LAPTM5. It forms a ternary complex with target proteins like KRASG12D, facilitating their relocation to lysosomes and resulting in ubiquitin-dependent degradation. This compound has potential for studying membrane protein regulation and devising strategies to counter resistance in KRAS-driven signaling pathways.Cor e Forma:SolidPeso molecular:1248.44BI1701963
BI1701963 is an orally effective inhibitor that targets the SOS1 and KRAS interaction, specifically inhibiting the activation of KRAS by blocking its GTP loading. This compound is utilized in cancer research to explore potential therapeutic effects against KRAS-driven malignancies.Fórmula:C47H62N8O4SCor e Forma:SolidPeso molecular:835.11SS47
CAS:SS47 is a PROTAC that degrades immunosuppressive HPK1 via proteasome; boosts BCMA CAR-T cell cancer therapy.Fórmula:C49H56N6O12SCor e Forma:SolidPeso molecular:953.07
